Estrogen replacement therapy and prognosis after first myocardial infarction

American Journal of Epidemiology

Volumn 145, Issue 3, 1997, Pages 269-277

  Newton, Katherine M ^a,b   LaCroix, Andrea Z ^a,b   McKnight, Barbara ^b,c   Knopp, Robert H ^b   Siscovick, David S ^b   Heckbert, Susan R ^b   Weiss, Noel S ^b,c  

^a CENTER FOR HEALTH STUDIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c USA   (United States)

Author keywords

estrogen replacement therapy; myocardial infarction; prognosis

Indexed keywords

ESTROGEN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; DRUG SAFETY; ESTROGEN THERAPY; FEMALE; HEART REINFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MENOPAUSE; MORTALITY; PROGNOSIS; RISK ASSESSMENT; UNITED STATES;

EID: 0031026471     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a009100     Document Type: Article

References (42)

1. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev 1985;7:80-104.
2. Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199-210.
3. Norman SG, Studd JWW. A survey of views on hormone replacement therapy. Br J Obstet Gynaecol 1994;101:879-87.
4. Gillum RF, Fortmann SP, Prineas RJ, et al. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 1984;108:150-8.
5. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 1995;5:275-85.
6. Psaty BM, Heckbert AR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-9.
7. Saunders KW, Stergachis A, VonKorff MV. Group Health Cooperative of Puget Sound. In: Strom BL, ed. Pharmacoepidemiology. Second ed. Chichester, England: John Wiley & Sons, 1994.
8. VonKorff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
9. Kleinbaum DJ, Kupper LL, Morgenstern H. Epidemiologic research principles and quantitative methods. New York, NY: Van Norstrand Reinhold, 1982.
10. Cox DR, Oakes D. Analysis of survival data. London, England: Chapman and Hall, 1984.
11. Lobo RA. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991;73:925-30.
12. Hernandez-Avila MK, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology 1990;1:128-33.
13. Burch J, Byrd B, Vaughn W. The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol 1974;118:778-82.
14. Bush T, Barrett-Connor E, Cowan L, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-Up Study. Circulation 1987;75:1102-9.
15. Criqui MH, Suarez L, Barrett-Connor E, et al. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogenous community. Am J Epidemiol 1988;128:606-14.
16. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989;298:165-8.
17. Eaker ED, Castelli WP. Differential risk for coronary heart disease among women in the Framingham Study. In: Eaker E, Packard B, Wenger N, et al., eds. Coronary heart disease in women. New York, NY: Haymarket Doyma, 1987:122-30.
18. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821-8.
19. Hammond C, Jelovsek F, Lee K, et al. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979;133:525-36.
20. Henderson BE, Ross RK, Paganini-Hill A, et al. Estrogen use and cardiovascular disease. Am J Obstet Gynecol 1986;154:1181-6.
21. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol 1988;159:312-17.
22. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
23. Lafferty FW, Helmuth DO. Post-menopausal estrogen replacement: the prevention of osteoporosis and systemic effects. Maturitas 1985;7:147-59.
24. MacMahan B. Cardiovascular disease and non-contraceptive oestrogen therapy. In: Oliver MF, ed. Coronary heart disease in young women. New York, NY: Churchill Livingstone, 1978:197-207.
25. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987;70:289-93.
26. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease, ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
27. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
28. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med 1985;313:1038-43.
29. Wolf PH, Madans JH, Finucane FF, et al. Reduction of cardiovascular disease related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991;164:489-94.
30. Sullivan JM, Vander-Zwagg R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-62.
31. Adams MR, Washburn SA, Wagner JD, et al. Arterial changes, estrogen deficiency and effects of hormone replacement. In: Lobo RA, ed. Treatment of the postmenopausal women: basic and clinical aspects. New York, NY: Raven Press, Ltd., 1994.
32. Sarrel PM. Blood flow. In: Lobo RA, ed. Treatment of the postmenopausal women: basic and clinical aspects. New York, NY: Raven Press Ltd., 1994.
33. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.
34. Meilahn EN, Kuller LH, Matthews KA, et al. Hemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992;2:445-55.
35. Psaty BM, Heckbert SR, Atkins D, et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med 1993;153:1421-7.
36. Hemminki E, Malin M, Topo P. Selection to postmenopausal therapy by women's characteristics. J Clin Epidemiol 1993;46:211-19.
37. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med 1992;115:455-6.
38. Gallagher EJ, Viscoli CM, Horwitz RI. The relationship of treatment adherence to the risk of death after myocardial infarction in women. JAMA 1993;270:742-4.
39. Petitti DB. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol 1994;4:115-18.
40. Hemminki E, Topo P, Malin M, et al. Physicians' views on hormone therapy around and after menopause. Maturitas 1993;16:163-73.
41. Sullivan JM. Atherosclerosis and estrogen replacement therapy. Int J Fertil Menopausal Stud 1994;39 (Suppl. 1):28-35.
42. Rosenberg L. Hormone replacement therapy: the need for reconsideration. Am J Public Health 1993;83:1670-3.